End Users, Procurement and Service Models for MRI-Guided Radiotherapy Systems

Why Procurement Model Follows End User Type

Buying an MRI-guided radiotherapy system is a project rather than a transaction. It involves a clinical case, a building, a budget, a procurement process and a long-term service relationship, and the way those elements fit together depends on who the buyer is.

Across the global MRI-guided radiation therapy systems market, the same platform may be bought outright by a university hospital, leased by a private operator and obtained through a partnership by a research institution, so the buyer type is the best predictor of how the purchase is structured.

This page describes the six end user types, four procurement models, six service categories and four regulatory and certification alignment categories tracked in this report as one buying framework. They are treated as market segments only, and certification schemes appear purely as market-access categories.

The framework has a logic. End user type determines who holds the budget and who makes the decision. Procurement model describes how the budget is committed. Service category describes what is bought alongside the platform. Certification alignment describes the access categories a supplier must satisfy to be considered.

Decision-maker roles in the category include radiation oncology directors, oncology physicists, chief medical officers, hospital procurement heads, chief science officers and clinical technology committees. The mix differs by end user, which explains much of the variation in sales cycles.

Sales cycles for the category run from 9 to 24 months, covering clinical evaluation, technical validation, budget approval and installation approvals, and procurement teams plan around that timeline rather than treating the purchase as a short-cycle decision.

Budget ownership is similarly varied. Oncology departments, hospital executive boards, research funding programs and government healthcare initiatives each hold budgets for this equipment, and the owner of the budget is often not the person who will use the platform, which lengthens the path from interest to approval.

Academic Medical Centers, Comprehensive Cancer Centers and University Hospitals

Academic medical centers, comprehensive cancer centers and university hospitals are the three end user types most associated with early and reference-site adoption of MRI-guided platforms. They combine large radiation oncology departments with research missions.

Academic medical centers use advanced platforms to support research and teaching as well as treatment, and a platform is often tied to a research program, a clinical trial or a collaboration with a supplier.

Comprehensive cancer centers are organized around cancer care and typically run a wide range of radiotherapy programs, which gives them a case for evaluating platforms that serve several modalities and treatment sites at once.

University hospitals sit between the two. They have the scale of a large hospital and often the academic links of a medical center, and their budgets are frequently shaped by hospital executive boards and, in some regions, by public funding.

Together these end users form the largest end user category in this report, and they are the group in which procurement committees, clinical evaluation periods and physics reviews are most formal.

Their purchases also have effects beyond their own installations. A visible academic installation becomes a reference for other buyers, and clinical trial participation requirements can direct other centers toward the same platform.

Specialty Clinics, Multi-Site Networks and Research Institutions

Specialty radiation oncology clinics, multi-site oncology networks and research institutions complete the end user dimension. Each differs from the academic group in scale, budget structure or purpose.

Specialty radiation oncology clinics are focused providers, often privately owned, with a narrower program set. Their decisions are closer to the owner or operator and depend heavily on whether a platform fits their patient volume and business plan.

Multi-site oncology networks must consider how a platform fits across locations, and treatment modalities these centers offer shape whether one site becomes a hub for adaptive or stereotactic programs while others run conventional work.

Research institutions buy for investigation more than for volume. Their requirements center on open interfaces, data access and collaboration with suppliers, and research funding programs are a typical source of the budget.

Buyer scale in the category runs from enterprise hospital networks to mid-sized specialty operators and single-site advanced cancer treatment centers. Smaller buyers feel the capital and infrastructure burden more, which is why they are more likely to seek leasing or managed arrangements.

Key buying triggers in the category include the wish to expand radiation oncology capability, competitive differentiation for cancer centers, participation requirements for clinical trials and interest in adaptive treatment. Each trigger points toward a different end user and a different procurement route, which is why the same platform is sold in several ways.

Public and private buyers also differ. Government cancer institutes and public hospitals tend to use tender-based acquisition, while private operators and nonprofit cancer centers more often negotiate directly, and these differences shape supplier go-to-market choices.

Direct Purchase, Leasing, Managed Equipment and Partnership Models

Four procurement models are tracked in this report: direct capital purchase, leasing and managed equipment agreements, vendor-managed service contracts and long-term oncology infrastructure partnerships. They differ in when and how a center pays and who carries the risk.

Direct capital purchase is the traditional route, in which the center buys the platform from its capital budget and manages service separately or under a contract. It suits well-funded buyers and gives the most control, but it requires the largest upfront commitment.

Leasing and managed equipment agreements spread the cost over time, so a center can add a platform without a single large capital outlay. This is useful to buyers with limited capital, and it can also provide a route to technology refresh.

Vendor-managed service contracts place maintenance, upgrades and sometimes operational support with the supplier for a defined term. Buyers use them to make costs predictable and to reduce the technical burden on in-house teams.

Long-term oncology infrastructure partnerships go furthest, aligning the supplier and the center over many years, often with research collaboration and shared goals. They are most often seen with academic centers and networks that want a strategic relationship.

Service contracts in the category are often multi-year agreements, and buyers compare them for coverage of software upgrades, remote support and training entitlements rather than looking only at the annual cost, since the contract shapes how the platform is kept current.

Procurement frameworks also vary. Tender-based acquisition, clinical evaluation procurement, long-cycle capital budgeting and public-private frameworks are all used, and a supplier must be able to work within whichever applies to the buyer.

Installation, Maintenance, Upgrade and Training Service Categories

Six service categories are tracked in this report: installation and commissioning, software upgrades, clinical workflow consulting, preventive maintenance, remote diagnostics, and training and certification services. They are bought alongside the platform rather than after it.

Installation and commissioning bring the platform into operation. Because the system involves a magnet and a delivery unit, the site must be prepared in advance, and the installation phase is one of the longest parts of the procurement timeline.

Software upgrades keep the platform current. They are a recurring category, and the frequency and content of upgrades is a feature suppliers present when they describe their roadmap to a buyer.

Clinical workflow consulting and training and certification services help a center establish and expand its programs, particularly adaptive ones, where staff must learn new steps and the team must be organized around them.

Preventive maintenance and remote diagnostics support day-to-day availability. Remote diagnostics allow a supplier to monitor and troubleshoot a platform without a site visit, which is valued by multi-site organizations and by centers far from supplier support bases.

The procurement lifecycle links these categories together: clinical evaluation, technical validation, budget approval, committee review, and then installation and commissioning. Service providers are usually involved from the technical validation stage, because site preparation and training plans must be agreed before the budget is approved.

Total cost of ownership across these categories matters to buyers, including infrastructure, training, upgrades and lifecycle maintenance. Service capability therefore features in supplier selection alongside the platform itself.

Certification and Accreditation as Market-Access Categories

The fourth group in this framework covers regulatory and certification alignment: FDA-approved systems, CE-certified systems, regional radiation safety compliance and hospital accreditation-linked procurement. This report treats them strictly as market-access categories.

That means the report records which access categories a supplier or system is associated with and how they enter procurement, and it makes no statement about what any scheme requires or whether any system satisfies it.

Access categories affect procurement in practical ways. A buyer in a given region will only shortlist systems carrying the certification relevant to that region, and tender documents frequently list certification as a threshold condition.

Hospital accreditation-linked procurement is a related category, in which a center's accreditation program shapes the equipment and service documentation it requires from suppliers.

Access categories therefore influence which of the companies covered in this report can bid in a given region, and they are one reason supplier presence differs between regions.

Because certification differs by region, suppliers plan market entry around it, and the go-to-market chapters of the full report record how access routes vary between North America, Europe and Asia-Pacific.